Bayer Aktiengesellschaft (BAYRY)
| Market Cap | 54.48B +72.3% |
| Revenue (ttm) | 52.16B -2.9% |
| Net Income | -2.49B |
| EPS | -2.53 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 10.84 |
| Dividend | 0.02 (0.17%) |
| Ex-Dividend Date | Apr 28, 2026 |
| Volume | 26,512 |
| Open | 13.58 |
| Previous Close | 13.80 |
| Day's Range | 13.43 - 13.61 |
| 52-Week Range | 7.19 - 15.23 |
| Beta | 0.83 |
| Analysts | Buy |
| Price Target | 15.23 (+13.4%) |
| Earnings Date | Aug 4, 2026 |
About Bayer Aktiengesellschaft
Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and ge... [Read more]
Financial Performance
In 2025, Bayer Aktiengesellschaft's revenue was 45.58 billion, a decrease of -2.21% compared to the previous year's 46.61 billion. Losses were -3.62 billion, 41.8% more than in 2024.
Financial numbers in EUR Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for BAYRY stock is "Buy." The 12-month stock price target is $15.23, which is an increase of 13.40% from the latest price.
News
Bayer, Henry Ford Health partner to expand access to clinical trials
Bayer (BAYRY) and Henry Ford Health announced a strategic partnership to expand clinical trial opportunities for patients. The work brings together Bayer’s global drug development expertise with Henry...
Bayer and Henry Ford Health Announce Strategic Research Partnership to Expand Patient Access to Clinical Trials
DETROIT--(BUSINESS WIRE)--Bayer, a global life sciences company, and Henry Ford Health today announced a strategic partnership to expand clinical trial opportunities for patients. The work brings toge...
Sabanto announces oversubscribed Series B funding led by Leaps by Bayer
Sabanto announced an oversubscribed Series B funding led by Leaps by Bayer (BAYRY) with participation by Sustainable Forward Capital, InnoVenture Iowa, Fulcrum Global Capital, DCVC, and Yara. The roun...
Pesticide makers stack wins against US environmental, public health groups
The U.S. Supreme Court handed a major legal victory to German agrichemical and pharmaceutical company Bayer last month when it reined in thousands of lawsuits accusing the German company of failing to...
Apollo to Acquire Stake in Bayer's Long-Acting Contraceptive Business for â¬3 Billion
Apollo to Acquire Stake in Bayer's Long-Acting Contraceptive Business for â¬3 Billion
Bayer (BAYRY) Secures â¬3B Equity Investment to Strengthen Capital Structure
Bayer (BAYRY) Secures â¬3B Equity Investment to Strengthen Capital Structure
Bayer secures EUR 3B to improve capital structure
Bayer (BAYRY) has secured EUR 3B in equity capital to improve its capital structure. The company signed a respective agreement with the global asset management firm Apollo (APO) on Friday.
Bayer Sells $3.4 Billion Contraceptives Stake to Apollo
Bayer AG sold a minority stake in its contraceptives business to Apollo Global Management Inc. for €3 billion ($3.4 billion) and will use the funds raised to help cover its ballooning litigation costs...
Apollo to Buy $3.4 Billion Stake in Bayer Contraceptives Business
The asset-management firm agreed to buy a minority stake in Bayer's long-acting reversible contraceptives business.
Bayer gets €3 billion in Apollo deal for contraceptives unit
Bayer said on Friday it had secured €3 billion ($3.4 billion) in equity from Apollo-managed funds in a deal tied to its long-acting reversible contraceptives, or LARC, business, aiming to bolster i...
EQS-Adhoc: Bayer Aktiengesellschaft: Bayer secures 3.0 billion euros to improve capital structure
EQS-Ad-hoc: Bayer Aktiengesellschaft / Key word(s): Other Bayer Aktiengesellschaft: Bayer secures 3.0 billion euros to improve capital structure 10-Jul-2026 / 07:54 CET/CEST Disclosure of an inside in...
Farm groups saved Bayer in court over RoundUp cancer claims. Five days later, Bayer called for tariffs on the ingredient farmers rely on
A tariff petition on Chinese glyphosate, a key RoundUp ingredient, has turned Bayer's biggest legal allies into its loudest critics
Bayer enters alliace with University of Colorado Anschutz, UCHealth
Bayer (BAYRY) announced a new strategic alliance focused on clinical trials collaboration with the University of Colorado Anschutz, UCHealth and Children’s Hospital Colorado, establishing Bayer’s firs...
Bayer (BAYRY) Surges 9% on Business Consolidation and Supreme Court Ruling
Bayer (BAYRY) Surges 9% on Business Consolidation and Supreme Court Ruling
Bayer Consolidates U.S. Glyphosate Business Into Ruveon
(RTTNews) - Bayer AG (BYR.L, BAYRY.PK, BAYZF.PK, BAY.MI, BAYN.DE) on Thursday said it has consolidated its U.S. glyphosate business into a new entity, Ruveon LLC, as part of its Crop Science division'...
DAX Up Nearly 0.5%; Bayer Up Sharply
(RTTNews) - The German market gained in strength on Thursday, in line with other major markets in Europe, as easing concerns about inflation and interest rates helped lift investor sentiment.
Bayer upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank upgraded Bayer (BAYRY) to Buy from Hold with a price target of EUR 60, up from EUR 45. The firm says last week’s Supreme Court ruling is pivotal…
Bayer Group (BAYRY) Launches Ruveon LLC to Streamline U.S. Glyphosate Operations
Bayer Group (BAYRY) Launches Ruveon LLC to Streamline U.S. Glyphosate Operations
Bayer fuels break-up talk as Roundup business put into separate unit
Bayer BAYGn.DE said on Thursday it was consolidating its U.S. Roundup business in a new unit, less than a week after scoring a major legal victory that blocked thousands of state-court lawsuits relat...
Following High-Court Victory, Bayer Separates Roundup Business
Bayer Group announces consolidation of U.S. glyphosate business into Ruveon
Bayer (BAYRY) Group announced the consolidation of the U.S. glyphosate business into Ruveon LLC to optimize and align the business with the specific needs of the U.S. market environment. Ruveon…
The weed killer America can’t afford to lose
A 7-2 Supreme Court decision protects Bayer from costly litigation over Roundup. Thank goodness.
Bayer removed from European Conviction List at Goldman Sachs
Goldman Sachs analysts removed Bayer (BAYRY) from the firm’s European Conviction List as part of its monthly update.
Bayer seeks US duties on Chinese-made glyphosate, angering farmers
June 30 (Reuters) - Bayer asked Washington to impose duties on glyphosate, the chemical used in the company's weedkiller Roundup, imported from China, saying it was being sold at artificially low pr...
Bayer's $7.25 billion Roundup settlement gets August hearing date
A Missouri state court on Tuesday set an August 19 hearing date to review Bayer's $7.25 billion proposed settlement of lawsuits alleging that its weedkiller Roundup causes cancer, briefly delaying a h...